Introduction
============

Mycosis fungoides (MF) is a cutaneous malignant lymphoma usually with CD4^+^ T cell phenotype ([@b1-mco-0-0-02085]) representing almost the 50% of all primary cutaneous lymphomas and more than 70% of cutaneous T-cell lymphomas (CTCLs) ([@b2-mco-0-0-02085]). This disease typically begins affecting the skin with a sequential appearance of patches followed by plaques and has tumors as final outcome. There are several clinical variants of MF including bullous, follicular, granulomatous, pustular, hyperkeratotic, hyperpigmented or hypopigmented, adnexotropic, and purpuriform forms ([@b2-mco-0-0-02085]). Several authors currently consider Sezary syndrome as an erythrodermic leukemic variant of MF, but in the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas, it is classified separately as an aggressive form of CTCL ([@b3-mco-0-0-02085]). In the late stages, MF may have a systemic dissemination with involvement of various organs such us lymph node/peripheral blood, liver, spleen, lung, bone marrow, gastrointestinal tract, pancreas, and kidney. Gastrointestinal (GI) lesions have been reported in some MF patients, although they are mentioned in the literature very rarely ([@b2-mco-0-0-02085]). In most cases, GI lymphomas are non-Hodgkin type and are commonly characterized by proliferating B cells while infiltrating T cells are observed less frequently. T-cell lymphomas are classified into enteropathy associated T-cell lymphoma (EATL), nasal type NK cell lymphoma and other types unassociated with enteropathy (WHO 2018 classification) ([@b4-mco-0-0-02085]). Few cases of association between GI lymphoma and MF are reported in literature. Mycosis fungoides represents the most frequent CTCL and usually affects middle-aged men ([@b5-mco-0-0-02085]) with a 2:1 male to female ratio. This malignancy typically involves the skin, mainly in unexposed areas such as trunk, buttocks and thighs ([Fig. 1](#f1-mco-0-0-02085){ref-type="fig"}) even if, in the later stages, lymph node and visceral involvement can be observed. The neoplastic infiltrate in MF is mainly represented by CD4^+^ cells ([Fig. 2](#f2-mco-0-0-02085){ref-type="fig"}) that express the T-cell receptor-β and are incline to loss the expression of surface markers such as CD2, CD3, CD5, CD7 and CD26 at variable extent. Notably, the loss of CD7 and CD5 is frequently observed in MF and up to 20% of cases exhibit a CD8^+^ phenotype ([@b6-mco-0-0-02085]). Clinical and immunophenotypic variants of MF include folliculotropic (follicular mucinosis), bullous, hypopigmented, psoriasiform and palmoplantar forms. The prognostic significance of these variants is still not clear. The prognosis directly correlates with the extent of skin involvement as well as to the presence of extracutaneous disease. Here we present a case of a 65 years old woman, affected by MF who developed a gastric T-cell lymphoma. According to our current knowledge this is the first case described in the scientific literature.

Case report
===========

A 65 years old woman came along to our observation at Dermatology Department in January 2012, presenting a cutaneous eruption characterized by the occurrence of multiple and extensive inflammatory erythematous patches, slightly scaly. The main diameter of patches ranged, in average, from 2 cm to more than 10 cm and lesions were primarily located on the buttocks, abdomen and legs ([Fig. 1](#f1-mco-0-0-02085){ref-type="fig"}). Some lesions had annular appearance with an erythematous and infiltrative border. The patient reported that skin clinical manifestations appeared since ten years before the establishment of a diagnosis of lymphomatoid contact dermatitis. Topical corticosteroid therapy was recommended, but it led to very poor benefit. Because of the referred worsening of cutaneous clinical manifestations, we decided to perform new biopsies of skin lesions and immunohistochemical analysis revealed an epidermotropic lymphocytic infiltrate. The histological and immunohistochemical procedures were carried out according to the previously described methods ([@b4-mco-0-0-02085],[@b7-mco-0-0-02085],[@b8-mco-0-0-02085]). The immunohistochemical analyses, performed by using the antibodies listed in [Table I](#tI-mco-0-0-02085){ref-type="table"}, revealed a pattern with simultaneous presence of CD3^+^, CD4^+^ and CD7^−^ antigens, confirming the diagnosis of MF ([Fig. 2](#f2-mco-0-0-02085){ref-type="fig"}). A topical corticosteroid treatment was prescribed while the patient was undergoing to an attentive follow-up. Due to the appearance of GI symptoms such as gastric pain, an esophagogastroduodenoscopy (EGD) procedure was performed, revealing the presence of an ulcerative nodule into the gastric mucosa. The histological analysis of this tissue revealed a widespread proliferation of lymphoid elements with small and medium size with destruction of gastric glandular structures. Mitotic figures and apoptotic bodies were also evident. The immunohistochemical studies characterized the lymphocytic infiltrates CD3^+^, CD43^+^, CD4^+^, CD20^−^, CD30^−^ TdT^−^, CD99^−^. These results were compatible with the histological diagnosis of gastric T-cell lymphoma ([Fig. 3](#f3-mco-0-0-02085){ref-type="fig"}). Several cycles of IFNα-based therapy were carried out, administered according classic protocols at a dose of 1.5 MU/day s.c. or i.m. during the first week and increased up to 3 MU/day s.c. or i.m. in the second week ([@b9-mco-0-0-02085]), resulting in clinical benefit and disease stabilization. However, clinical progression of gastric and skin lesions was observed after one year of treatment. Skin lesions further progressed to tumor stage generating large and diffused nodules on the trunk. Patient was hospitalized for planning alternative treatments but clinical conditions rapidly worsened and the patient died within few weeks for metabolic acidosis and multi organ failure.

Discussion
==========

MF should be differentiated from benign and malignant conditions that report similar clinicopathologic features ([@b10-mco-0-0-02085]). Several T-cell lymphomas and rarely B-cell lymphomas can display epidermotropic infiltrates, but MF should be also distinguished from various benign inflammatory conditions, including lymphomatoid drug eruptions, lichenoid keratosis, lymphomatoid eczematous dermatitis and the inflammatory stage of lichen sclerosus. Very rarely, other lymphoproliferative disorders such as Castleman\'s disease or Castleman-like conditions must be considered in the differential diagnosis of MF, especially when multicentric or an anomalous pattern is manifested ([@b11-mco-0-0-02085]). Primary GI lymphomas are not common diseases, occurring more frequently in the 6th decade of age and in males ([@b15-mco-0-0-02085],[@b16-mco-0-0-02085]). There is evidence that tissue resident immune cells, also in CTCLs, have the potential to strongly shape the tissue microenvironment and influence behavior malignant lesions, both participating in many inflammatory and immune reactions or regulating them ([@b17-mco-0-0-02085],[@b18-mco-0-0-02085]). These types of cancers can affect the whole GI tract, particularly stomach and small intestine; esophagus, colon and rectum are involved less frequently. Extracutaneous dissemination is reported in less than 10% of patients with patch or plaque-accompanied disease and in 30-40% of patients with tumors or generalized erythrodermatous involvement ([@b3-mco-0-0-02085]). In early stages, MF could be hardly differentiated from inflammatory cutaneous conditions, even in hands of experienced pathologists. Here because sometimes, this disease may follow its indolent and silent course for many years ([@b19-mco-0-0-02085]). In the later stages the organs most commonly affected are lymph nodes (60%), spleen (50%), lungs (43%), liver (41%), bone (27%), kidney (27%), tongue and mucous membranes (19%), heart (17%), pancreas (17%), and thyroid (14%) ([@b2-mco-0-0-02085]). Complications within the gastrointestinal tract are rarely described in literature. Also, the GI involvement can be primary or spread out from cutaneous disease. The principal papers regarding this topic are listed in [Table II](#tII-mco-0-0-02085){ref-type="table"}. MF can affect, albeit rarely, every section of the GI tract from the mouth to the rectum, but also the biliary tract and pancreas. The involvement of the GI tract in most cases can run torpidly displaying non-specific symptoms. However, some reports showed abrupt and fatal complications such as small bowel obstruction ([@b20-mco-0-0-02085]) and massive haemorrhage from an ulcerated tumor\'s nodule in the stomach ([@b5-mco-0-0-02085]). In our case MF had an indolent course for several years until gastric involvement became apparent. The immunohistochemical study of the neoplastic lymphocyte infiltrate has provided consistent results for gastric and skin localization. In fact, in both cases the T lymphocyte population was represented almost exclusively by CD4^+^ elements with only rare CD8^+^ lymphocytes. At that time, the disease became aggressive with nodules arising on skin plaques until, after one year of treatment, the patient died. Taking into account these data and considering the small number of cases documented in the literature, we feel like to affirm that gastric involvement in the context of MF is underestimated and then could be not so rare. Therefore, from clues we can glean that are skin manifestations getting worse, the appearance of gastric pain or other gastrointestinal symptoms it follows that MF must be carefully evaluated because the picture could be indicative of an actual systemic T-cell lymphoma and probably carrying back a poor prognosis.
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![Macroscopic appearance. (A) Typical early patch with erythema and mild scale plaques are presented. (B) Typical plaques with raised, infiltrative and palpable borders, clearing in the center and overlying scale.](mco-13-03-02085-g00){#f1-mco-0-0-02085}

![Skin biopsy. Histologic examination of a plaque stage lesion with neoplastic bands of dermal lymphocyte infiltrate. Marked epidermotropism is evident. H&E staining observed under (A) magnification, x100 and (B) x400. Immunophenotype is classically (C) CD3^+^ (magnification, x400), (D) CD4^+^ (magnification, x400), (E) CD8^−^ (magnification, x400) and (F) CD20^−^ (magnification, x100).](mco-13-03-02085-g01){#f2-mco-0-0-02085}

![Small bowel biopsy. (A) High degrees of lymphocytic infiltrate is present within the mucosa, as evidenced via H&E staining (magnification, x40). The framed section in the same panel is magnified in (B) (magnification, x100). Immunophenotype is (C) CD3^+^ (magnification, x40), (D) CD8^−^ (magnification, x40), (E) CD4^+^ (magnification, x100), (F) CD20^−^ (magnification, x100). In (F), strong and localized immunoreactivity is mainly due to the lymphatic follicles of mucose associated lymphoid tissue.](mco-13-03-02085-g02){#f3-mco-0-0-02085}

###### 

Antibodies employed for immunohistochemistry.

  Antibody    Source/clonality   Dilution   Company
  ----------- ------------------ ---------- ----------------------------------
  Anti-CD3    Mouse/monoclonal   1:500      Leica Biosystem
  Anti-CD4    Mouse/monoclonal   1:100      Leica Biosystems
  Anti-CD8    Mouse/monoclonal   1:50       Leica Biosystems
  Anti-CD20   Mouse/monoclonal   1:200      Dako; Agilent Technologies, Inc.

###### 

A collection of reports on GI tract localization in MF.

  GI involvement   Location, (no of cases)                                     Authors                                (Refs.)
  ---------------- ----------------------------------------------------------- -------------------------------------- ------------------------
  P                Small-bowell (1)                                            Camisa and Goldstein, 1981             ([@b21-mco-0-0-02085])
  P                Esophagus (1)                                               Redleaf *et al*, 1993                  ([@b22-mco-0-0-02085])
  S                Stomach (7) Small-bowell (13)                               Epstein *et al*, 1972                  ([@b23-mco-0-0-02085])
  S                Oesophagus (4) Stomach (4) Small-bowell (6) Pancreas (12)   Rappaport and Thomas, 1974             ([@b24-mco-0-0-02085])
  S                Oesophagus (1)                                              Kim *et al*, 1990                      ([@b25-mco-0-0-02085])
  S                Small-bowell (1)                                            Velagapudi *et al*, 2011               ([@b20-mco-0-0-02085])
  S                Biliary tract (1)                                           Madsen *et al*, 1999                   ([@b26-mco-0-0-02085])
  S                Pancreas (1)                                                Gottlieb *et al*, 2008                 ([@b27-mco-0-0-02085])
  S                Duodenal papilla (1)                                        Gómez-Venegas and Vargas-Rubio, 2016   ([@b7-mco-0-0-02085])
  S                Rectum (1)                                                  Tan *et al*, 2016                      ([@b28-mco-0-0-02085])
  S                Oral cavity (1) Small-bowell (1)                            Emge *et al*, 2016                     ([@b29-mco-0-0-02085])
  S                Small-bowell (1)                                            Chen *et al*, 1998                     ([@b30-mco-0-0-02085])

P, primary cutaneous disease; S, spreading from cutaneous disease; MF, mycosis fungoides; GI, gastrointestinal.
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